Evidence map›Paper›PMID 35523832›Full record

ArticleScientific reports2022

The balancing role of distribution speed against varying efficacy levels of COVID-19 vaccines under variants.

Daniel Kim, Pınar Keskinocak, Pelin Pekgün, İnci Yildirim

Abstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Daniel KimH. Milton Stewart School of Industrial and Systems Engineering, Georgia Institute of Technology, North Ave NW, Atlanta, GA, 30332, USA.
Pınar KeskinocakH. Milton Stewart School of Industrial and Systems Engineering, Georgia Institute of Technology, North Ave NW, Atlanta, GA, 30332, USA. pinar@isye.gatech.edu.ORCID 0000-0003-2686-546X
Pelin PekgünMoore School of Business, University of South Carolina, Columbia, SC, 29208, USA.
İnci YildirimDepartment of Pediatrics, Section of Infectious Diseases and Global Health, Yale School of Medicine, Yale Institute of Global Health, 1 Church Street, New Haven, CT, 06510, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During a pandemic, vaccination plays an important role in reducing the infection spread or adverse outcomes such as hospitalizations and deaths. However, a vaccine's overall public health impact depends not only on its initial efficacy, but also its efficacy against emerging variants and ease and speed of distribution. For example, mutations in SARS-CoV-2 raised concerns about diminishing vaccine effectiveness against COVID-19 caused by particular variants. Furthermore, due to supply-chain challenges, the accessibility and distribution of the vaccines have been hindered in many regions, especially in low-income countries, while the second or third wave of the COVID-19 pandemic has occurred due to the variants. Hence, we evaluated the interactions between the speed of distribution and efficacy against infection of multiple vaccines when variants emerge by utilizing a Susceptible-Infected-Recovered-Deceased model and assessing the level of infection attack rate. Our results show that speed is a key factor to a successful immunization strategy to control the pandemic even when the emerging variants may reduce the efficacy of a vaccine. Understanding the interactions between speed and efficacy and distributing vaccines that are available as quickly as possible are crucial to eradicate the pandemic before new variants spread.

Indexed as

COVID-19VaccinesCOVID-19 VaccinesHumansPandemicsSARS-CoV-2VaccinationCOVID-19 VaccinesVaccines

Identifiers

PMID35523832
PMCPMC9075929

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.